Acute bronchitis: clinical guidelines

The article deals with the issues of epidemiology and pharmacotherapy of acute bronchitis in adults. Acute bronchitis is one of the most pressing challenges in modern pulmonology, which is associated with a high incidence reaching 30–40 ‰ every year. The data on the prevalence of the disease, current ideas on the etiology of acute bronchitis, and trends of pharmacotherapy are presented. Acute bronchitis is a disease of viral etiology and it is inappropriate to use antimicrobial drugs to treat this disease. The widespread use of antibiotics, on the contrary, is accompanied by several adverse events, increased cost of treatment and the rise of antibiotic resistance. A special attention is paid to the markers of inflammatory response such as C-reactive protein and procalcitonin, their role in deciding on the need for antibacterial therapy for this disease. The article provides a critical analysis of the options for using inhaled bronchodilators and steroids to treat acute bronchitis. The clinical picture of acute bronchitis may include an acute onset, the presence of symptoms caused by upper and lower respiratory events, symptoms of intoxication of varying severity. The primary symptom of acute bronchitis is a cough, which is usually productive, with the discharge of a small amount of mucous and, sometimes, purulent sputum. Among the recommended drugs to treat acute bronchitis are mucoactive drugs, as cough is the main symptom of this disease. The results of presented studies showed that the combination drugs had the most pronounced mucoactive effect in acute bronchitis. For example, a drug containing bromhexine hydrochloride, guaifenesin and salbutamol demonstrated greater efficacy in reducing the duration of cough than mucoactive drugs being compared in the study in patients with acute respiratory viral infections and a long history of smoking.

1. Bartlett J.G., Dowell S.F., Mandell L.A., File T.M.Jr., Musher D.M., Fine M.J. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000;31(2):347–382. doi: 10.1086/313954.

2. Wenzel R.P., Fowler A.A. 3rd. Clinical practice. Acute bronchitis. N Engl J Med. 2006;355(20):2125–2130. doi: 10.1056/NEJMcp061493.

3. Albert R.H. Diagnosis and treatment of acute bronchitis. Am Fam Physician. 2010;82(11):1345–1350. Available at: https://www.aafp.org/afp/2010/1201/p1345.html.

4. Zaitsev A.A., Kulagina I.Ts. Аcute bronchitis. Farmateka = Farmateca. 2015;(14). (In Russ.) Available at: https://pharmateca.ru/en/archive/article/31936.

5. Knutson D., Braun C. Diagnosis and management of acute bronchitis. Am Fam Physician. 2002;65(10):2039–2044. Available at: https://pubmed.ncbi.nlm.nih.gov/12046770.

6. Wark P. Bronchitis (acute). BMJ Clin Evid. 2015;2015:1508. Available at: https://pubmed.ncbi.nlm.nih.gov/26186368.

7. Meza R.A., Bridges-Webb C., Sayer G.P., Miles D.A., Traynor V., Neary S. The management of acute bronchitis in general practice: results from the Australian Morbidity and Treatment Survey, 1990–1991. Aust Fam Physician. 1994;23(8):1550–1553. Available at: https://pubmed.ncbi.nlm.nih.gov/7980155.

8. Macfarlane J., Holmes W., Gard P., Macfarlane R., Rose D., Weston V. et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax. 2001;56(2):109–114. doi: 10.1136/thorax.56.2.109.

9. Smucny J., Fahey T., Becker L., Glazier R. Antibiotics for acute bronchitis. Cochrane Database Syst Rev. 2004;(4):CD000245. doi: 10.1002/14651858.CD000245.pub2.

10. Gonzales R., Bartlett J.G., Besser R.E., Cooper R.J., Hickner J.M., Hoffman J.R. et al. Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis: background. Ann Intern Med. 2001;134(6):521–529. doi: 10.7326/0003-4819-134-6-200103200-00021.

11. Irwin R.S., Baumann M.H., Bolser D.C., Boulet L.P., Braman S.S., Brightling C.E. et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1S):1S–23S. doi: 10.1378/chest.129.1_suppl.1S.

12. Zaitsev A.A., Budoragin I.E., Isaeva E.I., Vetrova E.I., Tyusheva V.V., Ivanova N.A. Pharmacotherapy of Acute Bronchitis: Setting Priorities. Antibiotiki i khimioterapiya = Antibiotics and Chemotherapy. 2019;64(1–2):44–49. (In Russ.) doi: 10.24411/0235-2990-2019-10008.

13. Tackett K.L., Atkins A. Evidence-based acute bronchitis therapy. J Pharm Pract. 2012;25(6):586–590. doi: 10.1177/0897190012460826.

14. Hart A.M. Evidence-based diagnosis and management of acute bronchitis. Nurse Pract. 2014;39(9):32–39. doi: 10.1097/01.NPR.0000452978.99676.2b.

15. Wadowsky R.M., Castilla E.A., Laus S., Kozy A., Atchison R.W., Kingsley L.A. et al. Evaluation of Chlamydia pneumoniae and Mycoplasma pneumoniae as etiologic agents of persistent cough in adolescents and adults. J Clin Microbiol. 2002;40(2):637–640. doi: 10.1128/JCM.40.2.637-640.2002.

16. Riffelmann M., Littmann M., Hülße C., Hellenbrand W., Wirsing von König CH. Pertussis: not only a disease of childhood. Dtsch Arztebl Int. 2008;105(37):623–628. doi: 10.3238/arztebl.2008.0623.

17. Zaitsev A.A. Trends of pharmacotherapy and prevention of acute respiratory viral infections. RMZH = RMJ. 2009;(23):1525. (In Russ.) Available at: https://www.rmj.ru/articles/infektsionnye_bolezni/Napravleniya_farmakoterapii_i_profilaktiki__ostryh_respiratornyh_virusnyh_infekciy/

18. Woodhead M., Blasi F., Ewig S., Garau J., Huchon G., Ieven M. et al. Guidelines for the management of adult lower respiratory tract infections – summary. Clin Microbiol Infect. 2011;17(Suppl. 6):1–24. doi: 10.1111/j.1469-0691.2011.03602.x.

19. Kostenko N.A., Kamkin E.G., Avdeyev S.N., Adamyan L.V., Baranov A.A., Baranova N.N. et al. Prevention, diagnosis, and treatment of novel coronavirus infection (COVID-19): interim guidelines, version 4 of March 27, 2020. (In Russ.) Available at: https://www.garant.ru/products/ipo/prime/doc/73712452/

20. Bent S., Saint S., Vittinghoff E., Grady D. Antibiotics in acute bronchitis: a metaanalysis. Am J Med. 1999;107(1):62–67. doi: 10.1016/S0002-9343(99)00167-9.

21. Huang N., Morlock L., Lee C.H., Chen L.S., Chou Y.J. Antibiotic prescribing for children with nasopharyngitis (common colds), upper respiratory infections, and bronchitis who have health-professional parents. Pediatrics. 2005;116(4):826–832. doi: 10.1542/peds.2004-2800.

22. Llor C., Moragas A., Bayona C., Morros R., Pera H., Cots J.M. et al. Effectiveness of anti-inflammatory treatment versus antibiotic therapy and placebo for patients with non-complicated acute bronchitis with purulent sputum. The BAAP Study protocol. BMC Pulm Med. 2011;11:38. doi: 10.1186/1471-2466-11-38.

23. Smucny J., Fahey T., Becker L., Glazier R. Antibiotics for acute bronchitis. Cochrane Database Syst Rev. 2004;(4):CD000245. doi: 10.1002/14651858.CD000245.pub2.

24. Sinopalnikov A.I., Zaicev A.A. Clinical efficacy and safety of step-down azithromycin monotherapy in patients with community-acquired pneumonia in hospital settings. Farmateka = Farmateca. 2006;(16):66–72. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/6667.

25. Zaytsev A.A., Okovityi S.V. Cough: Differential diagnosis and rational pharmacotherapy. Terapevticheskiy arkhiv = Therapeutic Archive. 2014;86(12):85– 91. (In Russ.) doi: 10.17116/terarkh2014861285-91.

26. Klyachkina I.L. Treatment of cough in ARVI and flu. RMZH = RMJ. 2012;(6):278. (In Russ.) Available at: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Lechenie_kashlya_pri_ORVI_i_grippe/

27. Prabhu Shankar S., Chandrashekharan S., Bolmall C.S., Baliga V. Efficacy, safety and tolerability of salbutamol + guaiphenesin + bromhexine (Ascoril) expectorant versus expectorants containing salbutamol and either guaiphenesin or bromhexine in productive cough: a randomised controlled comparative study. J Indian Med Assoc. 2010;108(5):313–320. Available at: https://pubmed.ncbi.nlm.nih.gov/21121410.